Ardelyx's kidney disease drug reduces elevated phosphate levels in late-stage study
(Reuters) - Ardelyx Inc said on Tuesday its experimental drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease in a late-stage study.
The treatment, Tenapanor, showed a greater difference in serum phosphorus levels compared to placebo, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.